IOM issues 4 recommendations for clinical data sharing

Laura Pedulli | | Health Exec | Quality

The Institute of Medicine has released four recommendations urging significant changes in how clinical trial data are shared, reports Modern Healthcare. 

IOM's recommendations are as follows:

1. Data sharing should be the expectation and the norm.

2. A fully analyzable set of data should be available no later than 18 months after a study's completion.

3. Strategies should be implemented to encourage data sharing, including the creation of technological platforms, boosting financial support and creating incentives.

4. The fourth recommendation calls ons sponsors of a study to take the lead on making the recommendations happen.

Read more below:

IOM urges vast changes in clinical trial data sharing

Laura Pedulli

Related Content

FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight
The top 25 children's heart hospitals in the US
Study ranks US health system dead last among wealthy nations
The 25 top US hospitals for diabetes care
The 25 best heart hospitals in the United States

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.